证券代码：688222 证券简称：成都先导 公告编号：2025-056 成都先导药物开发股份有限公司 关于对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易实施尚需履行的审批及其他相关程序 本次对外投资事项已经公司第三届董事会第三次会议、第三届董事会战略与 可持续发展委员会第一次会议审议通过，根据《上海证券交易所科创板股票上市 规则》（以下简称《" 上市规则》"）《成都先导药物开发股份有限公司章程》（以下 简称《" 公司章程》"）等规定，本次交易无需提交股东会审议。 其它需要提醒投资者重点关注的风险事项 投资标的：摩熵智能技术（成都）有限公司（以下简称"摩熵智能"或 "目标公司"或"标的公司"）； 投资金额：本次对外投资由成都先导药物开发股份有限公司（以下简称 "成都先导"或"公司"）合并报表范围内的成都蓉创先导股权投资基 金合伙企业（有限合伙）（以下简称"蓉创先导基金"）作为投资主体使 用自有资金 4,000 万元向目标公司进行增资，认购其新增注册资本 624.4898 万元。本次增资完成后 ...

成都先导公告，使用自有资金4000万元向摩熵智能增资，认购其新增注册资本624.49万元。增资完成 后，蓉创先导基金将取得目标公司51%股权，成为目标公司控股股东。 ...

南财智讯12月19日电，成都先导公告，公司合并报表范围内的成都蓉创先导股权投资基金合伙企业（有 限合伙）使用自有资金4,000.00万元向摩熵智能技术（成都）有限公司进行增资，认购其新增注册资本 624.49万元。本次增资完成后，蓉创先导基金将持有目标公司51%股权，取得其控制权，并纳入公司合 并报表范围。本次交易不构成关联交易，亦不构成重大资产重组。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出4.95亿元，游资资金净流出1823.62万元，散户资 金净流入5.13亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月19日医疗服务板块较上一交易日上涨1.6%，成都先导领涨。当日上证指数报收于 3890.45，上涨0.36%。深证成指报收于13140.22，上涨0.66%。医疗服务板块个股涨跌见下表： ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing at 3890.45 points, above the half-year line, reflecting a gain of 0.36% and a total trading volume of 1.748742 trillion yuan [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3890.45 points, above the half-year line, with a gain of 0.36% [1] - Total trading volume in the A-share market reached 1.748742 trillion yuan [1] Group 2: Stocks Breaking Half-Year Line - A total of 266 A-shares have surpassed the half-year line, indicating strong market interest [1] - Notable stocks with significant deviation rates include: - GQY Vision (10.23%) - Hongwei Technology (9.84%) - Zhongwang Fabric (8.75%) [1] Group 3: Detailed Stock Data - GQY Vision: Today's price increased by 11.23% with a turnover rate of 13.78%, latest price at 7.23 yuan [1] - Hongwei Technology: Today's price increased by 12.30% with a turnover rate of 17.12%, latest price at 27.49 yuan [1] - Zhongwang Fabric: Today's price increased by 9.98% with a turnover rate of 1.78%, latest price at 25.78 yuan [1]

Group 1 - The Shanghai Composite Index closed at 3887.81 points, above the six-month moving average, with a gain of 0.30% [1] - The total trading volume of A-shares reached 1,390.087 billion yuan [1] - A total of 249 A-shares have surpassed the six-month moving average, with notable stocks including GQY Vision, Hongwei Technology, and Zhongwang Fabric, showing significant deviation rates of 12.05%, 9.88%, and 8.75% respectively [1] Group 2 - GQY Vision (300076) had a daily increase of 13.08% with a turnover rate of 10.52%, and its latest price was 7.35 yuan, showing a deviation rate of 12.05% [1] - Hongwei Technology (688711) increased by 12.34% with a turnover rate of 15.68%, latest price at 27.50 yuan, and a deviation rate of 9.88% [1] - Zhongwang Fabric (605003) rose by 9.98% with a turnover rate of 1.76%, latest price at 25.78 yuan, and a deviation rate of 8.75% [1]

Group 1 - The core viewpoint of the news highlights a significant increase in the Shanghai Stock Exchange's Sci-Tech Innovation Board Innovative Drug Index, with a rise of 3.26% as of December 19, 2025, driven by strong performances from constituent stocks such as Chengdu Xian Dao (up 10.44%) and Yifang Bio (up 9.82%) [1] - The recent announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the 2025 National Basic Medical Insurance Drug List includes 114 new drugs, of which 50 are innovative drugs, marking an 88% success rate, a 12 percentage point increase from 2024 [3] - The total R&D investment by innovative drug companies on the Sci-Tech Innovation Board reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [4] Group 2 - The collaboration between Innovent Biologics and Takeda Pharmaceutical regarding three innovative cancer drugs has been completed, with Innovent receiving a total upfront payment of $1.2 billion, including a strategic investment of $100 million, and potential milestone payments of up to $10.2 billion [5] - The CXO industry is entering a new high prosperity cycle, driven by external improvements, including overseas interest rate cuts and domestic recovery, with a focus on innovative drug companies benefiting from policy support and innovation upgrades [6] - The implementation of the "Medicare + Commercial Insurance" multi-layered medical security system is seen as a substantial breakthrough, with nearly 90% of new drugs approved by Sci-Tech Board biopharmaceutical companies included in the insurance list [3][4]

早盘AI医疗概念震荡回升，华人健康涨近15%，此前鹭燕医药2连板，美年健康、安必平、成都先导、 塞力医疗跟涨。 ...

Group 1 - The CRO index experienced a 2% increase during intraday trading, indicating a broad upward trend among constituent stocks [1] - Notable performers included Zhaoyan New Drug, which rose over 9%, and Chengdu Xian Dao, which increased by 6.25% [1] - Other stocks such as Meidi Xi, Yinuosi, and Yaoshi Technology also saw gains, contributing to the overall positive performance of the sector [1]

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]